2021
DOI: 10.1002/ijgo.13933
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of the depot gonadotropin‐releasing hormone agonist protocol on in vitro fertilization outcomes in young poor ovarian responders from POSEIDON group 3

Abstract: Objective To investigate whether the depot gonadotropin‐releasing hormone (GnRH) agonist protocol could improve in vitro fertilization (IVF) outcomes for young poor responders from POSEIDON group 3. Methods This retrospective cohort study was carried out from June 2017 to June 2020. A total of 451 patients were assigned to three groups depending on the ovarian stimulation protocols. The outcome parameters of IVF were compared in each group. Results Patients who received the depot GnRH agonist had significantly… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 9 publications
(13 citation statements)
references
References 25 publications
0
13
0
Order By: Relevance
“…These studies found that this long-acting GnRHa protocol could improve endometrial thickness, embryo implantation rate, clinical pregnancy rate, and live birth rate. [10][11][12][13][14]18 These results suggest that long-acting GnRH agonist could improve endometrial receptivity and not affect embryo quality.…”
Section: Discussionmentioning
confidence: 78%
“…These studies found that this long-acting GnRHa protocol could improve endometrial thickness, embryo implantation rate, clinical pregnancy rate, and live birth rate. [10][11][12][13][14]18 These results suggest that long-acting GnRH agonist could improve endometrial receptivity and not affect embryo quality.…”
Section: Discussionmentioning
confidence: 78%
“…We also observed that the total gonadotropin dose was lower, and the day of stimulation was shorter in the PPOS group than in the long GnRH agonist and antagonist groups. This may be due to the prolonged pituitary suppression in the long-agonist protocol which started from the mid-luteal phase of the previous cycle; moreover, prolonged pituitary downregulation by GnRHa might contribute to improving endometrial receptivity [ 17 ].…”
Section: Discussionmentioning
confidence: 99%
“…[18][19][20] Other studies found that the long-acting GnRHa long protocol could increase endometrial thickness on hCG days. 7,10,15 Therefore, this protocol could improve endometrial receptivity by increasing endometrial thickness.…”
Section: Discussionmentioning
confidence: 99%